Follistatin is a secreted glycoprotein required for female sex determination and early ovarian development, but the precise mechanisms regulating follistatin (Fst) gene expression are not known. Here, we investigate the roles of bone morphogenetic protein 2 (BMP2) and forkheaddomain transcription factor L2 (FOXL2) in the regulation of Fst expression in the developing mouse ovary. Bmp2 and Fst showed similar temporal profiles of mRNA expression, whereas FOXL2 protein and Fst mRNA were coexpressed in the same ovarian cells. In a cell culture model, both FOXL2 and BMP2 up-regulated Fst expression. In ex vivo mouse fetal gonad culture, exogenous BMP2 increased Fst expression, but this effect was counteracted by the BMP antagonist Noggin. Moreover, in Foxl2-null mice, Fst expression was reduced throughout fetal ovarian development, and Bmp2 expression was also reduced. Our data support a model in which FOXL2 and BMP2 cooperate to ensure correct expression of Fst in the developing ovary. Further, Wnt4-knockout mice showed reduced expression of Fst limited to early ovarian development, suggesting a role for WNT4 in the initiation, but not the maintenance, of Fst expression. (Endocrinology 152: 272-280, 2011) A lthough testes and ovaries have quite distinct structures and functions, they arise from the same embryonic organ primordia, the genital ridges. In mammals, testis fate is determined by the action of the Y-linked gene Sry, which initiates the differentiation of Sertoli cells (1). Ectopic expression of Sry in XX embryos causes testicular development and, therefore, XX sex reversal (2). Ovarian fate has been considered as a default pathway caused by the absence of the Sry gene. To date, many testis-specific genes have been discovered, and the mechanisms of testicular development have been studied intensively. In contrast, only a handful of ovarian-specific genes have been identified, and the relationship between theses genes is not yet clear.
A lthough testes and ovaries have quite distinct structures and functions, they arise from the same embryonic organ primordia, the genital ridges. In mammals, testis fate is determined by the action of the Y-linked gene Sry, which initiates the differentiation of Sertoli cells (1) . Ectopic expression of Sry in XX embryos causes testicular development and, therefore, XX sex reversal (2) . Ovarian fate has been considered as a default pathway caused by the absence of the Sry gene. To date, many testis-specific genes have been discovered, and the mechanisms of testicular development have been studied intensively. In contrast, only a handful of ovarian-specific genes have been identified, and the relationship between theses genes is not yet clear.
Follistatin (Fst) is one gene the expression of which is restricted to the developing ovary but not the developing testis (3, 4) . FST protein is a single-chain glycoprotein that binds to TGF␤-superfamily molecules such as activin and neutralizes their activity (5) . Fst is expressed in many organs such as neuronal tissues, kidney, liver, bone, heart, muscle, and skin (5, 6) , and Fst-null mice die within a few hours after birth due to skeletal deformities, muscle abnormalities, and growth failure, confirming a broad range of biological roles (7) .
FST was originally identified as an inhibitor of FSH secretion (8, 9) and was thought to have an important role in folliculogenesis and ovarian function (10, 11) . However, Fst-null mice also displayed partial XX sex reversal during embryogenesis, suggesting an earlier role for Fst in ovarian development (4) . For example, Fst deficiency causes development of a celomic blood vessel, normally a feature of testis development, in an XX gonad (4) . Further, primordial germ cells in Fst-null mice enter meiosis normally, but undergo massive apoptosis at 16.5 days post coitus (dpc) (4). It is not clear whether FST acts directly on germ cells to facilitate their development and/or survival, or whether these effects are mediated by action of FST on somatic development of the ovary.
An important question in early ovarian development is how Fst expression is regulated. Two candidate molecules have been suggested to up-regulate Fst expression, WNT4 and forkhead-domain transcription factor L2 (FOXL2). Wnt4 is considered one of the master genes for ovarian development. XX Wnt4 Ϫ/Ϫ mice are partially sex reversed as judged by criteria such as formation of the celomic blood vessel. Wnt4 Ϫ/Ϫ mice also show greatly reduced Fst expression at 14.5 dpc (4, 12) . Homozygous mutation of WNT4 in humans causes SERKAL syndrome, with fetal lethality and testes or ovotestes in XX fetuses (13) . Wnt4 is expressed in the mesonephric mesenchyme and celomic epithelium overlying the future gonads of both sexes at 9.5 dpc. At 11.5 dpc, Wnt4 expression is down-regulated in XY gonads, but persists in XX gonads (12) . The other current candidate for the up-regulation of Fst expression is FOXL2. FOXL2 is a forkhead transcription factor expressed mainly in somatic cells of female gonads and in developing eyelids (14) . The phenotype of mammalian models of Foxl2 deficiency varies from XX sex reversal in goats (15) to ovarian failure in mice and humans (14, 16, 17) . Foxl2 is considered essential for ovarian folliculogenesis and granulosa cell development independently of Wnt4 (18) . Overexpression of Foxl2 in mice results in an increase in Fst expression in 13.5 dpc XX gonads (19) . Conversely, in Foxl2-null mice, Fst expression is reduced in postnatal ovaries (20) . Taken together, these data suggested that Wnt4 and Foxl2 act upstream of Fst during ovarian development.
Recently, it has been reported that FOXL2 and Smaand Mad-related protein (SMAD)3 interact and synergistically up-regulate Fst expression in pituitary cells (21) . SMAD proteins function as intracellular signaling molecules transferring the signal induced by bone morphogenetic proteins (BMPs) at the cell membrane to the nucleus. BMPs are members of the TGF-␤ superfamily, and among them, Bmp2 is expressed in an ovary-specific manner during early gonad development. Wnt4 is thought to act upstream of Bmp2 in ovarian development (4, 22) . Loss of BMP2 function in mice is lethal during embryogenesis before sex is determined (4). However, gonad-specific SMAD1/5 heterozygous double knockout XX mice are infertile (23) , suggesting that BMP2 plays an important role in ovarian development. There have been reports of direct interaction between forkhead proteins and SMADs (24 -27) . On the basis of these observations, we hypothesized that BMP2 might play a role in regulating Fst expression during ovarian development.
We report here that the expression of Bmp2, Foxl2, and Fst overlapped during ovarian development in vivo, and that BMP2 and FOXL2 cooperatively up-regulated Fst expression in vitro. BMP2 also up-regulated Fst expression in ex vivo organ culture experiments, and its up-regulation was cancelled by the BMP antagonist Noggin. In Foxl2-null embryos, Fst and Bmp2 expression was significantly reduced, and in Wnt4-null mice, Fst expression was also reduced at early stages. These observations indicate that WNT4 may have a role in up-regulating Fst expression early in ovarian development, and that FOXL2 and BMP2 are required to maintain Fst expression. This is the first report to identify a molecular function for BMP2 during ovarian development.
Materials and Methods

Animals and cell lines
Mouse embryos were collected from timed matings of the Swiss Quackenbush and CD1 outbred strain, with noon of the day on which the mating plug was observed designated as 0.5 dpc. Embryos were sexed at 11.5 dpc using an X-linked green fluorescent protein marker (28) and at 12.5-16.5 dpc by gonadal morphology. Protocols and use of animals were approved by the Animal Welfare Unit of the University of Queensland.
Transfection into KK1 cells
Murine ovarian granulosa cell tumor-derived KK1 cells (29) were cultured in DMEM (Invitrogen, Carlsbad, CA)/F12 medium (Life Technologies, Inc., Gaithersburg, MD) with 10% fetal bovine serum at 37 C in 5% CO 2 . KK1 cells were plated at 1.5 ϫ 10 5 per well in six-well plates 24 h before transfection. Cells were transfected with 2 g or 4 g of plasmid using Lipofectamine 2000 (Invitrogen) according to the manufacturer's instruction. Total amount of transfected plasmid was standardized using the empty expression vector, pcDNA3.1(ϩ) (Invitrogen, V795-20) as control. Recombinant human BMP2 (355-BM) and recombinant mouse Noggin (1967-NG/CF) were purchased from R&D systems (Minneapolis, MN) and reconstituted in PBS. Foxl2 cDNA was amplified by RT-PCR from mouse embryonic gonad mRNA using 5Ј-and 3Ј-untranslated region primers and ligated into p-GEMT easy vector (Promega Corp., Madison, WI). To generate Foxl2 expression vector, coding sequence of Foxl2 was excised using EcoRI, blunted, and subcloned into blunted KpnI and EcoRI sites of pcDNA3.1 expression vector (Promega).
Quantitative real-time RT-PCR (qRT-PCR)
For transfected cells, total RNA was collected 48 h after cell transfection. For tissue analysis, embryonic gonads without mesonephroi were dissected in ice-cold PBS at the appropriate stages. Total RNA from cells and tissue was isolated using the RNeasy Mini Kit (QIAGEN, Chatsworth, CA) including deoxyribonuclease treatment. Total RNA (500 ng; KK1 or 300 ng; gonads) was used for the synthesis of cDNA using SuperScript III (Invitrogen) and random primers (Invitrogen), according to manufacturer's instructions. cDNA samples were diluted 1:4, and 1 l used in each 25 l qRT-PCR, containing SYBR green PCR master-mix (Applied Biosystems, Foster City, CA). Transcript levels were analyzed on an ABI Prism-7500 Sequence Detector System over 40 cycles of 95 C for 15 sec and 60 C for 1 min in a two-step thermal cycle, preceded by an initial 10-min step at 95 C. qRT-PCR primers are listed in Table 1 . The average and SEM of three biological replicates measured in triplicate was calculated. Rps29 (Ribosomal protein S29) served as the housekeeping gene to standardize qRT-PCR data based on minimum variability at each stage during gonadal development (30) . We used unpaired Student's t test to demonstrate statistical significant difference between the given sample and the control.
In situ hybridization and immunohistochemistry
In situ hybridization and immunohistochemistry were performed sequentially, and each procedure was performed as described previously (31) (32) (33) . Briefly, sections of paraformaldehyde-fixed, paraffin-embedded embryos were dewaxed, rehydrated, incubated in proteinase K, refixed with 4% paraformaldehyde, acetylated, and prehybridized. Hybridization was performed overnight at 60 C. After 2 h blocking, antidigoxigenin antibody at 1:2000 dilution in blocking solution was added, and sections were incubated overnight at 4 C. After washing, sections were equilibrated in NTM 100 mM Tris (pH9.5), 100 mM NaCl, 50 mM MgCl2 buffer and incubated in color solution. After In situ hybridization, immunohistochemistry was performed by washing in PBS, stimulating antigen retrieval by boiling for 8 min, and incubation with 0.3% H 2 O 2 . Thereafter, sections were washed in PBTx, blocked with 10% sheep serum, and incubated with primary antibody overnight at 4 C. Biotinylated secondary antibody was hybridized for 1 h. For color reaction, sections were incubated with streptavidin-horseradish peroxidase for 30 min at room temperature. Polyclonal anti-FOXL2 antibody was generated as described by Cocquet et al. (34) and used at 1:2000 dilution.
Ex vivo organ culture
Mouse gonads were collected from 11.5 dpc X-linked green fluorescent protein embryos. Four to six gonads were used in each group. First, gonads were incubated in culture medium (DMEM ϩ 10% fetal calf serum) with recombinant BMP2 (500 ng/ml) and/or recombinant Noggin (2 g/ml) for 1 h at 37 C. Thereafter, the gonads were incubated on filter membrane (Millipore filters, HAWPO1300) floating on culture medium containing BMP2 (500 ng/ml) or recombinant Noggin (2 g/ml) at 37 C in 5% CO 2 for 48 h. Total RNA was collected using the RNeasy Mini Kit (QIAGEN) with deoxyribonuclease treatment as described above.
Knockout mouse analysis
The generation of Wnt4-, Foxl2-, and double-knockout mice was previously reported (12, 16, 35) . These mice were maintained on a mixed C57B6/J/129/SVJ genetic background. For each genotype, gonads were separately processed and analyzed independently. In addition to the samples of 13.5 dpc and newborn (P0), we collected samples from Foxl2-null mice at 16.5 dpc, and Wnt4-null mice at 15.5 dpc. Total RNA was obtained from dissected gonads by enzymatic extraction (Melt; Ambion, Austin, TX) followed by linear RNA amplification using Pico Ovation (NuGEN). qRT-PCR (TaqMan) was performed using an ABI 7900HT system (Applied Biosystems). The average and SEM of three biological replicates measured in triplicate were calculated. Sdha was used as the housekeeping gene to standardize the data as reported previously (35) .
Results
Fst and Bmp2 have similar temporal expression profiles in fetal ovaries
To elucidate the relationships between Fst and other known ovarian genes, we performed a detailed time course expression analysis from 11.5 dpc to P0 using qRT-PCR analysis. As reported previously, Fst, Wnt4, Foxl2, and Bmp2 were expressed in an ovarian-specific manner (Fig.  1A ). In contrast, the genes encoding the receptors for BMPs, Bmpr1a and Bmpr2, did not show sexually dimorphic expression (Fig. 1A) .
To better compare the time course of these ovarian marker genes, we normalized the maximum expression levels of each gene to 100% (Fig. 1B) . Fst expression was detectable at 11.5 dpc at low levels, and increased thereafter until 13.5 dpc before decreasing again. The level of Wnt4 expression was already at a maximum at 11.5 dpc and decreased over the period investigated, consistent with the possibility that Wnt4 might play a more prominent role in initiating, rather than maintaining, Fst expression. In contrast, Foxl2 expression was first detectable at 12.5 dpc and continued to increase until P0, consistent with a later role in regulating Fst expression. The profile of Bmp2 expression was very similar to that of Fst at all time points examined, consistent with the hypothesis that BMP2 has an important role in regulating Fst expression.
Fst and FOXL2 are expressed in the same cells in fetal ovaries
Wnt4 and Bmp2 encode secreted factors, whereas Foxl2 encodes a transcription factor, and so the hypothesis that Foxl2 might be involved in Fst regulation requires that both genes/proteins are expressed in the same cells. Therefore, we next investigated the spatial distribution of Foxl2 and Fst expression by histological analysis. Due to the lack of a FST antibody that has sufficient sensitivity to detect expression in fetal gonads, we combined in situ hybridization (ISH) for Fst mRNA with immunohistochemistry for FOXL2 protein. In 13.5 dpc XX gonads, most FOXL2-positive cells also expressed Fst (Fig. 2) , supporting the suggested involvement of FOXL2 in regulating Fst expression in the developing mouse ovary.
FOXL2 and BMP2 cooperatively up-regulate endogenous Fst expression in vitro
To further investigate the potential involvement, and relative contributions, of BMP2 and FOXL2 in the regulation of Fst expression, we carried out a series of experiments using the cell line KK1 (29, 36) , derived from ovarian tumor cells of transgenic mice expressing simian virus 40 T-antigen. KK1 cells express Cyp19 and produce cAMP in response to human chorionic gonadotropin, FSH, and LH, suggesting that they are analogous to ovarian granulosa cells. KK1 cells were able to be transfected at high efficiency in our hands (Fig. 3A) . We found that transfection and expression of Foxl2 in KK1 cells up-regulated endogenous Fst expression in a dose-dependent manner (Fig. 3B) . Expression of another female-specific gene, Rspo1, did not change as a result of Foxl2 transfection (data not shown), indicating that Fst up-regulation is not the result of global increases in transcription. Similarly, treatment of the cells with exogenous BMP2 protein resulted in increased Fst expression (Fig. 3C) . Together, these data support a model in which FOXL2 and BMP2 might be involved in Fst regulation in the fetal ovary.
To investigate potential cooperative action of FOXL2 and BMP2 in stimulating Fst expression, we combined BMP2 treatment with Foxl2 transfection. Individually, Foxl2 transfection and BMP2 treatment up-regulated Fst expression approximately 3-and 2-fold, respectively. Combined treatment of Foxl2 and BMP2 resulted in a 10-fold up-regulation of Fst expression (Fig. 3D) , demonstrating a cooperative and mildly synergistic effect of FOXL2 and BMP2 on Fst expression. Using the same in vitro model system, Foxl2 expression was unaffected by BMP2 (Fig. 3E) , whereas Bmp2 was up-regulated by FOXL2 (Fig. 3F) . These data suggest that FOXL2 may exert its effects on Fst expression in the ovary through a combination of direct activation of the Fst promoter, cooperative interaction with one or more SMADs, and enhanced transcription of the gene encoding BMP2. To elucidate whether the regulation of Bmp2 by FOXL2 is essential for Fst up-regulation, we used BMP2 antagonist Noggin in KK1 cell culture. Noggin is a TGF-␤ binding protein that antagonizes TGF-␤ molecule function by interrupting its binding to receptors and plays an important role in dorsoventral patterning, limb formation, and neural tube morphogenesis during embryonic development (37) . In KK1 cells, Noggin abrogated the Fst regulation by BMP2 in a dose-dependent manner (Fig.  4A) , as expected. In the presence of Noggin, FOXL2 retained the ability to up-regulate Fst expression in KK1 cells (Fig. 4B) , indicating that the upregulation of Fst by FOXL2 likely occurs through a combination of direct effects on Fst expression and indirect effects mediated by up-regulation of Bmp2.
BMP2 up-regulates Fst expression ex vivo
Based on the in vitro data, we analyzed cultures of organ explants to elucidate the regulation of Fst in vivo. Mouse embryonic gonads were dissected at 11.5 dpc and cultured in medium containing BMP2 in the presence or absence of the inhibitor Noggin. Gene expression changes were evaluated by qRT-PCR. Incubation of XX genital ridges for 48 h with 500 ng/ml BMP2 resulted in strong up-regulation of Fst expression (Fig. 5A ). Lower concentration of BMP2 (100 ng/ml) and shorter incubation time (3, 6 , and 24 h) did not significantly up-regulate Fst expression (data not shown). In contrast, BMP2 did not up-regulate Foxl2 in cultured fetal ovaries (Fig. 5B ). In agreement with our findings using KK1 cells, Noggin abrogated the action of BMP2 in stimulating Fst expression (Fig. 5A) . Furthermore, Fst expression was up-regulated by exogenous BMP2 only in XX gonads, not in XY gonads (Fig. 5A) , presumably because the latter lack endogenous Foxl2 expression.
In vivo requirements for Fst up-regulation
For further investigation of Fst gene regulation in vivo, we analyzed Fst gene expression in XX gonads of Foxl2-null knockout mice at different stages of development. Fst expression was significantly reduced in Foxl2-null mice at 13.5 dpc and P0 (Fig. 6A ) and also at 
dpc, confirming that FOXL2 is upstream of Fst expression during ovarian development in vivo.
Because loss of Bmp2 function in mice is lethal during embryogenesis before sex is determined (4), we were unable to analyze the effect of Bmp2 knockout on Fst expression. However, because WNT4 has previously been implicated in affecting Fst expression at 14.5 dpc (4, 12), we analyzed Fst gene expression in XX gonads of Wnt4-null, and Foxl2/Wnt4 double knockout embryos at different stages of development. In Wnt4-null mice, Fst expression was remarkably reduced at 13.5 dpc, as reported previously (Fig. 6A) (4) . However, Fst expression had fully recovered to wild-type levels by P0 (Fig. 6A) . Analysis at the intervening time point of 15.5 dpc showed that most of the recovery had been achieved by this time (Fig. 6B) . These data suggest that although WNT4 has an important role for Fst expression in vivo, its role is limited to the early phase of Fst expression during ovarian development.
Finally, Foxl2/Wnt4 double knockout showed a complete loss of Fst expression comparable to that seen in wild-type XY gonads, at both 13.5 dpc and P0 (Fig. 6A) , suggesting that a combination of WNT4 priming and BMP2/ FOXL2 maintenance is required for Fst expression in the developing ovary.
Bmp2 requires Foxl2 at P0
Our experiments involving KK1 cells indicated that FOXL2 is able to influence Fst gene expression through a combination of direct effects on Fst and indirect effects mediated by up-regulation of Bmp2. To examine the possible regulation of Bmp2 by FOXL2 in vivo, we analyzed Bmp2 gene expression in XX gonads of Foxl2-null mice at a range of stages. Bmp2 expression was significantly reduced in Foxl2-null mice at P0 (Fig. 6C) , but not at 13.5 or 16.5 dpc (Fig. 6, C and D) . This observation confirms that FOXL2 is upstream of Bmp2 expression during ovarian development; however, its contribution is limited to later stages.
In contrast, in Wnt4-null mice, Bmp2 expression was compromised at all three stages examined (13.5 dpc, 15.5 dpc, P0; Fig. 6D ), consistent with published data (4). Foxl2/Wnt4 double knockout showed significantly reduced Bmp2 expression at both 13.5 dpc and P0, as expected (Fig. 6C) .
Discussion
In previous reports, FOXL2 and WNT4 have been suggested to regulate Fst expression during ovarian development (4, 19, 20, 35, 38, 39) . Our data suggest that BMP2 is another factor that regulates Fst expression and that it acts cooperatively with FOXL2. This is the first report to identify a molecular function for BMP2 during ovarian development. Observations of genetically modified mice have hinted at a causal relationship between FOXL2 and Fst expression (17, 19, 35) . Our present data extend these observations 1) by showing that Fst is coexpressed with FOXL2 in somatic cells during ovarian development, 2) by demonstrating that trans- expression in ex vivo gonadal organ culture was evaluated by using qRT-PCR. Gonads (11.5 dpc) were cultured on the medium containing BMP2 (500 ng/ml), or BMP2 (500 ng/ml) and Noggin (2 g/ml). Data represent mRNA expression relative to Rps29 (mean Ϯ SEM of three biologically independent experiments performed in triplicate). *, P Ͻ 0.05. In addition, the different temporal profiles of Fst and Foxl2 expression that we observed implicate additional factor(s) in the regulation of Fst in ovaries. The observation that Bmp2 and Fst have a very similar profile of expression during fetal ovary development suggests a major role for BMP2, and our finding that BMP2 up-regulates Fst expression in KK1 cells and in ex vivo organ culture of mouse fetal ovaries supports this conclusion. Several reports have shown a direct interaction between forkhead proteins and SMADs (24 -27) . Recently, it has been reported that FOXL2 and SMAD3 interact and synergistically up-regulate Fst expression in pituitary cells (21) . Our in vitro data indicate that BMP2 and FOXL2 cooperatively stimulate Fst expression by Foxl2 in fetal ovaries. This cooperative mechanism was also supported by the ex vivo organ culture analysis showing that BMP2 activated Fst expression in XX gonads, and not in XY gonads. The result suggests that a female-specific cofactor assisted BMP2 function, consistent with a role for endogenous FOXL2 as the cofactor. Overall, our data shed new light on the regulation of Fst expression and suggest that FOX/ SMAD cooperativity may be a more general phenomenon in developmental biology.
We have added further complexity to this picture by using Foxl2-null mice and cultured cells to show that Bmp2 expression is responsive to levels of FOXL2. Therefore, the observed effects of FOXL2 on Fst expression in the ovary may be mediated by a combination of direct activation of Fst transcription, interaction with one or more SMADs, and enhanced transcription of the gene encoding BMP2 (Fig. 7) , although the contribution of the Foxl2-BMP2 pathway is likely to be limited, given the modestly reduced expression of Bmp2 in Foxl2-knockout Ϫ/Ϫ and Wnt4 Ϫ/Ϫ XX gonads. All time points analyzed are shown. Data represent mRNA expression relative to XX wild-type (WT) gonads (mean Ϯ SEM of three biologically independent experiments performed in triplicate). *, P Ͻ 0.05; **, P Ͻ 0.01; ***, P Ͻ 0.001. mice at P0 but not at 13.5 or 16.5 dpc. Considering the Fst and Bmp2 expression levels at each stage in Foxl2-null mice, the contribution of each pathway changes in a stagedependent manner. Further studies will be required to identify the precise contribution of each pathway at each stage.
Our analyses also shed new light on the involvement of WNT4 in this system. At 13.5 dpc, Fst expression was markedly reduced in Wnt4-null mice but recovered thereafter. These observations suggest a new model in which WNT4 is likely to be important for the early stage (initiation) of Fst expression rather than for continued expression at later stages (maintenance). This model, depicted in Fig. 7 , is strongly supported by the different expression profiles of Wnt4 and Fst during ovarian development.
Considering the moderate impairment of the Fst expression in Wnt4 and Foxl2-null mice, the decrease in Fst expression in double-knockout mice was more dramatic than expected. This phenomenon could be explained by the fact that XX gonads in double-knockout mice showed similarities to testes, with tubules and abundant expression of SOX9 and anti-Müllerian hormone (35) that were not observed in Foxl2 or Wnt4 single-knockout mice (16, 17, 35) . Male-specific regulators such as SOX9 are known to suppress the ovarian developmental pathway (33) , and it is therefore likely that Sox9 up-regulation in the double mutant has an indirect effect on the expression of Fst in the double-knockout mice.
Our analysis of Fst expression in Foxl2-and Wnt4-knockout mice may also indicate a stage-dependent role for Fst in ovarian development. Previous studies have shown celomic vessel formation and germ cells survival are impaired in Fst-knockout embryos (4). Wnt4-null mice show a similar phenotype (12) , and our present analysis shows that ablation of WNT4 function corresponds with loss of Fst expression at early stages (11.5 dpc) but not later stages (15.5 dpc and later). Conversely, in Foxl2-null gonads, which do not show ectopic celomic vessel formation or germ cell defects (17) , Fst expression was higher at 11.5 dpc than at 15.5 dpc. These observations may indicate that the early expression of Fst is essential for inhibiting celomic vessel formation and ensuring survival of germ cells in XX gonads, although stage-specific ablation of Fst will be required to test this possibility.
In summary, our data suggest that FOXL2 and BMP2 regulate Fst expression cooperatively during fetal ovarian development. The contribution of WNT4, FOXL2, and BMP2 to the regulation of Fst is likely to be sequential and stage dependent. To initiate Fst expression, WNT4 appears to be the major regulator, whereas FOXL2 and BMP2 assume a more prominent role in maintenance of Fst expression. Our data contribute to a growing picture of the regulatory networks underpinning development of the mammalian ovary.
